B
MRNA icon

Bailard’s Moderna MRNA Stock Holding History

Bailard’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-738
Closed -$284K – 760
2021
Q3 		$284K Buy
+738
New +$272K 0.01% 548

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bailard's MRNA Position: Q4 2021 in Review

Bailard sold out of Moderna (MRNA) in Q4 2021, closing a stake of 738 shares — an estimated $284K sold.

Bailard first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $284K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Bailard reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
  • Bailard sold 738 Moderna shares in Q4 2021, an estimated $284K.
  • Bailard first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
  • Bailard's Moderna position peaked at $284K in Q3 2021.
  • 1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.